Sign in
Active, not recruitingPhase 3

Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

Key facts

Who runs it
Neurocrine Biosciences
Where
Ann Arbor, Atlanta, Aurora, Bethesda, Boston, Dallas, Great Neck, Indianapolis, Los Angeles, Minneapolis, New York, Philadelphia, Pittsburgh, Rochester, San Diego, San Francisco, Seattle, St Louis, Tulsa, and Winston-Salem, United StatesSee the 20 sitesAlso in 17 other countries, 42 sites
Status
Active, not recruiting
Phase
Phase 3
People taking part
182 people enrolled
Started
16 Dec 2020
Expected to end
Aug 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Crinecerfont
  • Placebo
Record updated
11 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Be willing and able to adhere to the study procedures, including all requirements at the study center and return for the follow-up visit
  • Have a medically confirmed diagnosis of classic CAH due to 21-hydroxylase deficiency
  • Be on a stable steroid regimen
  • Participants of childbearing potential must agree to use an acceptable method of contraception during the study

Who cannot take part

  • Have received any other investigational drug within 30 days before initial screening or plan to use an investigational drug (other than the study drug) during the study
  • Have current substance dependence, or current substance (drug) or alcohol abuse
  • Have had a blood loss ≥550 mL or donated blood or blood products within 8 weeks prior to the study
  • Have a history of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic glucocorticoid therapy
  • Have a clinically significant unstable medical condition or chronic disease other than CAH
  • Have a history of cancer unless considered cured
  • Have a known history of clinically significant arrhythmia or abnormalities on ECG
  • Have a known hypersensitivity to any corticotropin releasing hormone receptor antagonists
  • Have a diagnosis of any of the other known forms of classic CAH
  • Are pregnant

Where in United States

Also in 17 other countries, 42 sites

  • Ann Arbor, MichiganHospital not named in the registry
  • Atlanta, GeorgiaHospital not named in the registry
  • Aurora, ColoradoHospital not named in the registry
  • Bethesda, MarylandHospital not named in the registry
  • Boston, MassachusettsHospital not named in the registry
  • Dallas, TexasHospital not named in the registry
  • Great Neck, New YorkHospital not named in the registry
  • Indianapolis, IndianaHospital not named in the registry
  • Los Angeles, CaliforniaHospital not named in the registry
  • Minneapolis, MinnesotaHospital not named in the registry
  • New YorkHospital not named in the registry
  • Philadelphia, PennsylvaniaHospital not named in the registry
  • Pittsburgh, PennsylvaniaHospital not named in the registry
  • Rochester, New YorkHospital not named in the registry
  • San Diego, CaliforniaHospital not named in the registry
  • San Francisco, CaliforniaHospital not named in the registry
  • Seattle, WashingtonHospital not named in the registry
  • St Louis, MissouriHospital not named in the registry
  • Tulsa, OklahomaHospital not named in the registry
  • Winston-Salem, North CarolinaHospital not named in the registry

About the trial

What the trial wants to find out

This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult participants with classic CAH due to 21-hydroxylase deficiency. The study consists of a 24-week randomized, double-blind, placebo-controlled period, followed by 1 year of active treatment with crinecerfont. Subsequently, participants may elect to participate in the open-label extension (OLE) period. The duration of participation in the study is approximately 20 months for the core study and will be a variable amount of time per participant for the OLE (estimated to be approximately 3 years).

The 2 groups in the trial

  • PlaceboPlacebo, for comparison

    Placebo capsule, administered orally, twice daily for 24 weeks, followed by active treatment with crinecerfont for at least 1 year.

    Treatment: Crinecerfont and Placebo

  • CrinecerfontTreatment being tested

    Crinecerfont capsule, administered orally, twice daily for 24 weeks during the placebo-controlled treatment period, followed by active treatment with crinecerfont for at least 1 year.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
Publications
Record updated
11 May 2026